» Articles » PMID: 36929044

Profiling of Kidney Involvement in Systemic Lupus Erythematosus by Deep Learning Using the National Database of Designated Incurable Diseases of Japan

Overview
Publisher Springer
Specialty Nephrology
Date 2023 Mar 17
PMID 36929044
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Kidney involvement frequently occurs in systemic lupus erythematosus (SLE), and its clinical manifestations are complicated. We profiled kidney involvement in SLE patients using deep learning based on data from the National Database of Designated Incurable Diseases of Japan.

Methods: We analyzed the cross-sectional data of 1655 patients with SLE whose Personal Clinical Records were newly registered between 2015 and 2017. We trained an artificial neural network using clinical data, and the extracted characteristics were evaluated using an autoencoder. We tested the difference of population proportions to analyze the correlation between the presence or absence of kidney involvement and that of other clinical manifestations.

Results: Data of patients with SLE were compressed in a feature space in which the anti-double-stranded deoxyribonucleic acid (anti-dsDNA) antibody titer, antinuclear antibody titer, or white blood cell count contributed significantly to distinguishing patients. Many SLE manifestations were accompanied by kidney involvement, whereas in a subgroup of patients with high anti-dsDNA antibody titers and low antinuclear antibody titers, kidney involvement was positively and negatively correlated with hemolytic anemia and inflammatory manifestations, respectively.

Conclusion: Although there are various combinations of SLE manifestations, our study revealed that some of them are specific to kidney involvement. SLE profiles extracted from the objective analysis will be useful for categorizing SLE manifestations.

Citing Articles

Comparative analysis of kidney function prediction: traditional statistical methods vs. deep learning techniques.

Ohashi M, Ishikawa Y, Arai S, Nagao T, Kitaoka K, Nagasu H Clin Exp Nephrol. 2025; .

PMID: 39813007 DOI: 10.1007/s10157-024-02616-1.


Systemic lupus in the era of machine learning medicine.

Zhan K, Buhler K, Chen I, Fritzler M, Choi M Lupus Sci Med. 2024; 11(1).

PMID: 38443092 PMC: 11146397. DOI: 10.1136/lupus-2023-001140.


Demographics and treatment of patients with primary nephrotic syndrome in Japan using a national registry of clinical personal records.

Nakagawa N, Kimura T, Sakate R, Wada T, Furuichi K, Okada H Sci Rep. 2023; 13(1):14771.

PMID: 37679492 PMC: 10485053. DOI: 10.1038/s41598-023-41909-5.


Demographics and treatment of patients with primary membranoproliferative glomerulonephritis in Japan using a national registry of clinical personal records.

Nakagawa N, Kimura T, Sakate R, Isaka Y, Narita I Clin Exp Nephrol. 2023; 27(11):928-935.

PMID: 37515698 PMC: 10581954. DOI: 10.1007/s10157-023-02387-1.

References
1.
Ikeuchi H, Sugiyama H, Sato H, Yokoyama H, Maruyama S, Mukoyama M . A nationwide analysis of renal and patient outcomes for adults with lupus nephritis in Japan. Clin Exp Nephrol. 2022; 26(9):898-908. DOI: 10.1007/s10157-022-02232-x. View

2.
POLLAK V, PIRANI C, SCHWARTZ F . THE NATURAL HISTORY OF THE RENAL MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS. J Lab Clin Med. 1964; 63:537-50. View

3.
Kirou K, Dall Era M, Aranow C, Anders H . Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment. Front Immunol. 2022; 13:980079. PMC: 9472122. DOI: 10.3389/fimmu.2022.980079. View

4.
Hesaka A, Yasuda K, Sakai S, Yonishi H, Namba-Hamano T, Takahashi A . Dynamics of D-serine reflected the recovery course of a patient with rapidly progressive glomerulonephritis. CEN Case Rep. 2019; 8(4):297-300. PMC: 6820815. DOI: 10.1007/s13730-019-00411-6. View

5.
Newman K, Owlia M, El-Hemaidi I, Akhtari M . Management of immune cytopenias in patients with systemic lupus erythematosus - Old and new. Autoimmun Rev. 2013; 12(7):784-91. DOI: 10.1016/j.autrev.2013.02.001. View